Primary liver cancer is one of the most common malignant tumours in the world, and according to statistics, about half of liver cancers occur in China, which seriously threatens the lives and health of people around the world, especially in China. Hepatocellular carcinoma is the most common type, accounting for about 90 per cent of primary liver cancers. Most patients are asymptomatic in the early stage and fail to pay attention to it. Most of the patients are in the middle or late stage when they are first diagnosed, and only 20% - 30% of them can receive radical hepatectomy. Patients are through the treatment to make the tumour shrinkage and downstaging, to achieve the condition of resectable, that is, the conversion treatment. Conversion therapy has great potential for development and has now become an indispensable treatment for intermediate and advanced hepatocellular carcinoma. However, there are various treatment options for conversion therapy, no uniform guidelines to guide clinical selection, and the overall conversion rate is still low, so it is particularly important to explore appropriate conversion therapy options. This article mainly describes the existing conversion therapies, hoping to provide help and ideas for exploring the best conversion therapies in the future.
References
[1]
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020, GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
[2]
Sperber, A., Bangdiwala, S., Drossman, D., et al. (2021) Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology, 160, 99-114.E113.
[3]
Llovet, J.M., Kelley, R.K., Villanueva, A., et al. (2021) Hepatocellular Carcinoma. Nature Reviews Disease Primers, 7, Article No. 6. https://doi.org/10.1038/s41572-020-00240-3
[4]
Zeng, H., Chen, W., Zheng, R., et al. (2018) Changing Cancer Survival in China during 2003-15, a Pooled Analysis of 17 Population-Based Cancer Registries. The Lancet Global Health, 6, E555-E567. https://doi.org/10.1016/S2214-109X(18)30127-X
[5]
Lee, B.H., Lee, D.S., Cho, C.W., et al. (2019) Role and Limitation of Neoadjuvant Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocelluar Carcinoma Patients with Child-Pugh Class A. World Journal of Surgical Oncology, 17, Article No. 143. https://doi.org/10.1186/s12957-019-1685-6
[6]
Chen, X., Lai, L., Ye, J., et al. (2021) Downstaging Therapies for Unre-Sectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 11, Article ID: 740762. https://doi.org/10.3389/fonc.2021.740762
[7]
Zhang, Y., Huang, G., Wang, Y., et al. (2016) Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience. Oncologist, 21, 1442-1449. https://doi.org/10.1634/theoncologist.2016-0094
[8]
Hamaoka, M., Kobayashi, T., Kuroda, S., et al. (2017) Hepatectomy after Down-Staging of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Using Chemoradiotherapy: A Retrospective Cohort Study. International Journal of Surgery, 44, 223-228. https://doi.org/10.1016/j.ijsu.2017.06.082
[9]
Li, B., Liu, Y., Feng, Y., et al. (2022) Effects of Fu Zheng Detoxification and Elimination of Accumulation Formula Combined with Hepatic Artery Chemoembolisation on Immune Function and Survival of Patients with Primary Hepatocellular Carcinoma with Deficiency of Qi and Yin, Toxicity and Stasis. Journal of Traditional Chinese Medicine, 63, 1143-1148.
[10]
Wang, G.Y. (2021) Strategies and Current Status of Translational Therapy for Hepatocellular Carcinoma. Journal of Clinical Surgery, 29, 1012-1014.
[11]
Qin, J.L., Qin, W., Mo, S.T., et al. (2022) Research Progress of Translational Therapy for Hepatocellular Carcinoma. China Clinical New Medicine, 15, 461-465.
[12]
Specialised Committee on Clinical Diagnosis and Treatment Guidelines of the Interventionalists Branch of the Chinese Physicians Association (2021) Clinical Practice Guidelines for Transarterial Chemoembolisation (TACE) Treatment of Hepatocellular Carcinoma in China (2021 Edition). Chinese Medical Journal, 101, 1848-1862.
[13]
Orlacchio, A., Chegai, F., Merolla, S., et al. (2015) Downstaging Disease in Patients with Hepatocellular Carcinoma outside Up-to-Seven Criteria: Strategies Using Degradable Starch Microspheres Transcatheter Arterial Chemo-Embolization. World Journal of Hepatology, 7, 1694-1700. https://doi.org/10.4254/wjh.v7.i12.1694
[14]
Tsai, W.L., Sun, W.C., Chen, W.C., et al. (2020) Hepatic Arterial Infusion Chemotherapy vs Transcatheter Arterial Embolization for Patients with Huge Unresectable Hepatocellular Carcinoma. Medicine (Baltimore), 99, E21489. https://doi.org/10.1097/MD.0000000000021489
[15]
Kokudo, N., Takemura, N., Hasegawa, K., et al. (2019) Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC Guidelines) 2019 Update. Hepatology Research, 49, 1109-1113. https://doi.org/10.1111/hepr.13411
[16]
Choi, J.H., Chung, W.J., Bae, S.H., et al. (2018) Randomized, Prospective, Comparative Study on the Effects and Safety of Sorafenib vs. Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancer Chemotherapy and Pharmacology, 82, 469-478. https://doi.org/10.1007/s00280-018-3638-0
[17]
Song, D.S., Song, M.J., Bae, S.H., et al. (2015) A Comparative Study between Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Journal of Gastroenterology, 50, 445-454. https://doi.org/10.1007/s00535-014-0978-3
[18]
Lü, N., Kong, Y., Mu, L., et al. (2018) Hepatic Arterial Infusion of Oxaliplatin plus Fluorouracil/Leucovorin vs. Sorafenib for Advanced Hepatocellular Carcinoma. Journal of Hepatology, 69, 60-69. https://doi.org/10.1016/j.jhep.2018.02.008
[19]
Lü, N., Lin, Y.E., Kong, Y.N., et al. (2018) FOXAI: A Phase II Trial Evaluating the Efficacy and Safety of Hepatic Arterial Infusion of Oxaliplatin plus Fluorouracil/Leucovorin for Advanced Hepatocellular Carcinoma. Gut, 67, 395-396. https://doi.org/10.1136/gutjnl-2017-314138
[20]
Choi, J.H., Chung, W.J., Bae, S.H., et al. (2018) Randomized, Prospective, Comparative Study on the Effects and Safety of Sorafenibvs. Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancer Chemotherapy and Pharmacology, 82, 469-478. https://doi.org/10.1007/s00280-018-3638-0
[21]
Lyu, N., Kong, Y., Mu, L., et al. (2018) Hepatic Arterial Infusion of Oxaliplatin plus Fluorouracil/Leucovorinvs. Sorafenib for Advanced Hepatocellular Carcinoma. Journal of Hepatology, 69, 60-69. https://doi.org/10.1016/j.jhep.2018.02.008
[22]
Kudo, M., Matsui, O., Izumi, N., et al. (2014) Liver Cancer Study Group of Japan. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer, 3, 458-468. https://doi.org/10.1159/000343875
[23]
Xu, L., Chen, M.-S. and Hu, Z.-L. (2021) Role of Hepatic Arterial Perfusion Chemotherapy in the Translational Treatment of Hepatocellular Carcinoma. Chinese Journal of Practical Surgery, 41, 272-275.
[24]
Lencioni, R., De Baere, T., Soulen, M.C., et al. (2016) Lipiodol Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review of Efficacy and Safety Data. Hepatology, 64, 106-116. https://doi.org/10.1002/hep.28453
[25]
He, M.K., Le, Y., Li, Q.J., et al. (2017) Hepatic Artery Infusion Chemotherapy Using MFOLFOX versus Transarterial Chemoembolization for Massive Unresectable Hepatocellular Carcinoma: A Prospective Non-Randomized Study. Chinese Journal of Cancer, 36, 83-90. https://doi.org/10.1186/s40880-017-0251-2
[26]
Xue, T., Le, F., Chen, R., et al. (2015) Transarterial Chemoembolization for Huge Hepatocellular Carcinoma with Diameter over Ten Centimeters: A Large Cohort Study. Medical Oncology, 32, Article No. 64. https://doi.org/10.1007/s12032-015-0504-3
[27]
Sun, H.C., Zhou, J., Wang, Z., et al. (2022) Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma (2021 Edition). Hepatobiliary Surgery and Nutrition, 11, 227-252. https://doi.org/10.21037/hbsn-21-328
[28]
Pan, Y.X. and Chen, M.S. (2023) The Role of Vascular Intervention in the Comprehensive Treatment of Intermediate and Advanced Hepatocellular Carcinoma. Science and Technology Herald, 41, 52-57.
[29]
Ren, Z., Xu, J., Bai, Y., et al. (2021) Sintilimab plus a Bevacizumab Biosimilar (IBI305) versus Sorafenib in Unresectable Hepatocellular Carcinoma (ORIENT-32): A Randomised, Openlabel, Phase 2-3 Study. The Lancet Oncology, 22, 977-990. https://doi.org/10.1016/S1470-2045(21)00252-7
[30]
Finn, R.S., Qin, S.K., Ikeda, M., et al. (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. The New England Journal of Medicine, 382, 1894-1905. https://doi.org/10.1056/NEJMoa1915745
[31]
Professional Committee on Prevention and Control of Hepatobiliary and Pancreatic Diseases of the Chinese Preventive Medical Association, Professional Committee on Liver Cancer of the Chinese Anti-Cancer Association, Hepatology Group of the Surgical Branch of the Beijing Medical Association, et al. (2021) Chinese Expert Consensus on Translational Therapy for Advanced Hepatocellular Carcinoma Based on Immunotherapy and Targeted Regimens (2021 Edition). Chinese Journal of Hepatobiliary Surgery, 27, 241-251.
[32]
Ho, W.J., Zhu, Q., Durham, J., et al. (2021) Neoadjuvantcabozantinib and Nivolumab Convert Locally Advanced Hepatocellular Carcinoma into Resectable Disease with Enhanced Antitumor Immunity. Nature Cancer, 2, 891-903. https://doi.org/10.1038/s43018-021-00234-4
[33]
You, N., Peng, X., Li, J., et al. (2023) Hepatic Arterial Infusion Chemotherapy (HAIC) Combined with Regorafenib and PD-1 Inhibitors versus Regorafenib Combined with PD-1 Inhibitors for Secondline Treatment Hepatocellular Carcinoma (HCC). Annals of Oncology, 34, S605. https://doi.org/10.1016/j.annonc.2023.09.2122
[34]
Zhu, X., Feng, X., et al. (2022) The Safety and Efficacy of Lenvatinib Combined with TACE and PD-1 Inhibitors (LenTAP) versus TACE Alone in the Conversion Resection for Initially Unresectable Hepatocellular Carcinoma: Interim Results from a Multicenter Prospective Cohort Study. Annals of Oncology, 33, S323-S330. https://doi.org/10.1016/j.annonc.2022.07.839
[35]
Liu, M.M., Mu, H., Liu, C.F., et al. (2022) Hepatic Artery Infusion Chemotherapy (HAIC) Combined with Sintilimab and Bevacizumab Biosimilar (IBI305) for Initial Unresectable Hepatocellular Carcinoma (HCC): A Prospective, Single-Arm Phase Ⅱ Trial. Journal of Clinical Oncology, 40, 4073. https://doi.org/10.1200/JCO.2022.40.16_suppl.4073
[36]
Peng, Z., Fan, W., Zhu, B., et al. (2022) Lenvatinib Combined with Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase Ⅲ, Randomized Clinical Trial (LAUNCH). Journal of Clinical Oncology, 41, 117-127. https://doi.org/10.1200/JCO.22.00392
[37]
Li, Y.Z., Chen, K., Zhao, J., et al. (2022) Clinical Study of Hepatic Artery Perfusion Chemotherapy Combined with Immune and Targeted Therapy for Unresectable Hepatocellular Carcinoma. Journal of Practical Hospital Clinics, 19, 42-46.
[38]
He, M.K., Liang, R.B., Zhao, Y., et al. (2021) Lenvatinib, Toripalimab, plus Hepatic Arterial Infusion Chemotherapy versus Lenvatinib Alone for Advanced Hepatocellular Carcinoma. Therapeutic Advances in Medical Oncology, 13, 1-14. https://doi.org/10.1177/17588359211002720
[39]
Li, B., Qiu, J., Zheng, Y., et al. (2021) Conversion to Resectability Using Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma. Annals of Surgery, 2, e057. https://doi.org/10.1097/AS9.0000000000000057
[40]
Yuan, Y., He, W., Yang, Z., Qiu, J., Huang, Z., Shi, Y., Lin, Z., Zheng, Y., Chen, M., Lau, W.Y., Li, B. and Yuan, Y. (2023) TACE-HAIC Combined with Targeted Therapy and Immunotherapy versus TACE Alone for Hepatocellular Carcinoma with Portal Vein Tumourthrombus: A Propensity Score Matching Study. International Journal of Surgery, 109, 1222-1230. https://doi.org/10.1097/JS9.0000000000000256
